Together with the hematology department of the Erasmus University Medical Center Rotterdam (The Netherlands) we validated our patent that describes the use of our knowledge-based coagulation model for the analysis of the thrombin generation assay to accurately derive the fibrinogen concentration. Knowledge-based and/or data-driven analysis provides a powerful way to gain additional insights in the coagulation system of patients from standard functional assays.
Our model provides a clinically applicable method to identify sepsis/SIRS patients with a high probability to develop DIC well in advance
Our results indicate that anticoagulant treatment may benefit septic patients in terms of DIC development and outcome. This effect seems to be strongly dependent on the timing and duration of the anticoagulant treatment. Further (prospective, interventional) research studies are needed to substantiate our early findings.